MLV & Co Initiates Halozyme Therapeutics With Buy

Analysts at MLV & Co initiated coverage on

with a Buy rating. The target price for Halozyme Therapeutics is set to $12. Halozyme Therapeutics shares have dropped 42.48% over the past 52 weeks, while the S&P 500 index has gained 13.04% in the same period. Halozyme Therapeutics' shares fell 3.22% to close at $9.03 yesterday.